Compare MP & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MP | GH |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 14.1B |
| IPO Year | N/A | 2018 |
| Metric | MP | GH |
|---|---|---|
| Price | $62.94 | $102.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 21 |
| Target Price | $70.92 | ★ $79.19 |
| AVG Volume (30 Days) | ★ 10.4M | 2.4M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $232,742,000.00 | ★ $902,569,000.00 |
| Revenue This Year | $37.00 | $34.72 |
| Revenue Next Year | $145.29 | $26.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 26.44 | ★ 30.38 |
| 52 Week Low | $15.56 | $29.91 |
| 52 Week High | $100.25 | $112.43 |
| Indicator | MP | GH |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 56.90 |
| Support Level | $57.24 | $103.36 |
| Resistance Level | $61.66 | $109.59 |
| Average True Range (ATR) | 3.73 | 5.54 |
| MACD | 0.85 | -1.11 |
| Stochastic Oscillator | 68.76 | 42.83 |
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.